Indications for implantable cardioverter defibrillator and ablation therapy in arrhythmic mitral valve prolapse
Bulgarian Medical Journal, 2025, 19(2), 44-48.
B. Grigorova1, I. Daskalov1, L. Demirevska1, N. Grigorov2
1 Clinic of Cardiology, Military Medical Academy, MHAT – Sofia
2 Clinic of Internal Diseases, Military Medical Academy, MHAT – Sofia
Abstract. Mitral valve prolapse (MVP) is one of the most common structural changes of the heart. Although it is considered a benign condition, there are several complications that may occur. These are progressive mitral regurgitation with dilatation of the mitral annulus, impairment of the left ventricle function with a decrease in the ejection fraction and development of heart failure, pulmonary hypertension, infective endocarditis, ventricle arrhythmias (VAs) and sudden cardiac death (SCD). Sudden cardiac death in mitral valve prolapse is a frequent cause of death among young patients and athletes, therefore the aim of this literature review is to review the options for prevention in the high-risk groups. The placement of implantable cardioverter defibrillator (ICD) and the catheter ablation of VAs are modern possible treatment methods with specific and discussed indications. There are different studies that examine the indications and the outcomes. The current recommendations are based on them.
Key words: mitral valve prolapse, ventricle arrhythmia, sudden cardiac death, implantable cardioverter defibrillator, catheter ablation
Address for correspondence: Dr. Boryana Nedyalkova Grigorova, Cardiology Clinic, Military Medical Academy – Sofia, 3 Georgi Sofiyski St., BG – 1606 Sofia, tel: +359 884716620, e-mail: